Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)

September 22, 2026 updated by: Shandong Provincial Hospital

Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study

This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.

Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.

Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.

The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.

This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Stroke onset to randomization within 48 to 72 hours.
  4. Meets predefined clinical stability criteria before randomization.
  5. Unilateral upper extremity motor impairment on the dominant-hand side.
  6. Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
  7. Pre-stroke modified Rankin Scale (mRS) score ≤2.
  8. Written informed consent obtained from the participant or legally authorized representative.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Real EEG-BCI Training + Standard Early Rehabilitation

Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days.

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Sham Comparator: Sham BCI Training + Standard Early Rehabilitation

Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Time Frame: Baseline to Day 30 after randomization

The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score.

Baseline to Day 30 after randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Time Frame: Baseline, Day 10, Day 30, and Day 90

Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function.

Baseline, Day 10, Day 30, and Day 90
Action Research Arm Test (ARAT) Score
Time Frame: Baseline, Day 30, and Day 90

Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability.

Baseline, Day 30, and Day 90
National Institutes of Health Stroke Scale (NIHSS) Score
Time Frame: Baseline, Day 10, and Day 30

Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit.

Baseline, Day 10, and Day 30
Modified Rankin Scale (mRS) Score
Time Frame: Day 90

Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability.

Day 90
Modified Barthel Index (MBI) Score
Time Frame: Day 30 and Day 90

Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence.

Day 30 and Day 90

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Training Completion Rate
Time Frame: During the 10-day intervention period

Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions.

During the 10-day intervention period
Effective Training Duration
Time Frame: During the 10-day intervention period

Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period.

During the 10-day intervention period
EEG Signal Quality and BCI Performance Metrics
Time Frame: During the 10-day intervention period

Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available.

During the 10-day intervention period
Follow-up completion rate
Time Frame: Through Day 90

Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90.

Through Day 90
Protocol deviation rate
Time Frame: From randomization through Day 90

Feasibility outcome defined as the proportion of participants with one or more protocol deviations.

From randomization through Day 90
Incidence of symptomatic intracranial hemorrhage
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of any intracranial hemorrhage
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of neurological deterioration
Time Frame: From baseline through Day 90

Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation.

From baseline through Day 90
Incidence of seizures
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of seizure events after randomization.

From baseline through Day 90
Incidence of Falls or Injuries
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of falls during the study period.

From baseline through Day 90
Incidence of Cardiovascular and Vital Sign Events
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period.

From baseline through Day 90
Incidence of training-related discomfort
Time Frame: During the 10-day intervention period

Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention.

During the 10-day intervention period
Incidence of serious adverse events
Time Frame: From baseline through Day 90

Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events.

From baseline through Day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: QinJian Sun, MD, Shandong Provincial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

April 29, 2026

First Submitted That Met QC Criteria

May 8, 2026

First Posted (Actual)

May 13, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe